A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related genetic alterations
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2018
Price : $35 *
At a glance
- Drugs Lucitanib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology; Clovis Oncology Italy; EOS S.p.A.
- 12 Sep 2018 Status changed to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.